What happened
Kyongbo Pharmaceutical filed provisional (unaudited) separate results for Q1 2026: revenue of US$44.5M (+9.1% year on year), operating profit of US$479K (+489.3% year on year) and a net loss of US$356K.
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$44.5M |
|---|---|
| Revenue vs a year earlier | +9.1% |
| Operating profit | US$479K |
| Net income | −US$356K |
| Period | Q1 2026 (separate) |
| Filed | 2026-04-29, Operating results (preliminary) (fair disclosure) |
| Source | DART rcept 20260429800652 → open original filing |
Source: DART. Information only, not investment advice.